bioRxivPharmacology & Toxicology
Pharmacokinetics of Sustained-Release Buprenorphine and Extended-Release Buprenorphine in Mice with Surgical Catheterization
M. Saenz, E. A. Bloom-Saldana, T. Synold, R. W. Ermel, P. T. Fueger, J. B. Finlay
Abstract
The Guide for the Care and Use of Laboratory Animals strongly encourages the use of pharmaceutical grade chemicals and analgesics. The extra-label use of sustained-release buprenorphine (SRB) is commonly administered to rodents to mitigate moderate-to-severe pain. An FDA-indexed buprenorphine formulation, known as extended-release buprenorphine (XRB), has recently become available and is currently the only pharmaceutical grade slow-release buprenorphine approved for use in mice and rats. However, no studies have directly compared the pharmacokinetic (PK) parameters and therapeutic efficacy of SRB and XRB in surgically catheterized mice. Thus, we compared the plasma buprenorphine concentrations and PK parameters of SRB and XRB in mice after surgical catheterization. We hypothesized that mice treated with SRB or XRB would have circulating buprenorphine concentrations exceeding the therapeutic threshold for up to 72-hours post-operatively. Male and female C57Bl/6J mice were anesthetized, treated with either SRB (1 mg/kg, SC, once) or XRB (3.25 mg/kg, SC, once) and underwent surgical catheterization. At 6, 24, 48, and 72 h after SRB or XRB administration, arterial blood samples were collected. Post-operative weight loss was similar between groups with a decline of 11.7 {+/-} 1.6 and 12.3 {+/-} 0.7% in males and 7.6 {+/-} 2.2 and 8.1 {+/-} 1.1% (mean {+/-} SEM) in females treated with SRB and XRB, respectively. Both SRB and XRB maintained circulating buprenorphine concentrations above the therapeutic level of 1.0 ng/mL for 72 h after administration. XRB buprenorphine concentrations were significantly greater (3-4-fold) than SRB concentrations at 6, 24, and 48 h, commensurate with the increase dose concentration of XRB to SRB. These results support the use of either SRB or XRB for the alleviation of postoperative pain in mice. The new availability of FDA-indexed XRB increases the options for safe and effective pharmaceutical grade analgesia in rodents.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pharmacokinetics of Extended-release Buprenorphine (Ethiqa) in Female Yorkshire Swine (Sus scrofa domestica)
L. Stevey-Rindenow, M. M. Saenz, … P. T. Fueger·bioRxiv·Oct 4, 2023
- A Buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72h in mouse femoral fracture models
A. Wolter, C. H. Bucher, … A. Lang·bioRxiv·Jul 5, 2022
- Metabolic Cage Analysis of Surgically Catheterized C57Bl/6J Mice (Mus musculus) Treated with Carprofen and Sustained-release Buprenorphine
Jui Rose Tu, Marissa Saenz, … Patrick T. Fueger·Journal of the American Association for Laboratory Animal SciencePeer-reviewed·Nov 1, 2025
- Sublingual Buprenorphine/Naloxone Film in Unanesthetized Rats: Feasibility, Tolerability, and Plasma Exposure
Yao Wang, Qiang Chen, … Pei Tang·bioRxiv·Nov 3, 2026
- Subcutaneous and orally self-administered high-dose carprofen in male and female mice: pharmacokinetics, tolerability and impact on cage-side pain indicators
A. Glasenapp, J. P. Bankstahl, … M. Bankstahl·bioRxiv·Jun 3, 2023
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
V. Janganati, P. Salazar, … L. K. Brents·bioRxiv·Dec 12, 2022